TY - JOUR
T1 - SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation
AU - Rischall, Ariel
AU - Olson, Amanda
N1 - Publisher Copyright:
© 2024
PY - 2024
Y1 - 2024
N2 - Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity. Adoptive cell therapy with cytotoxic T lymphocytes (CTL) has proven to be both efficacious and safe in the management of post-transplant viral infections. Recent advances have led to faster production of CTLs and broadened applications for their use. In particular, the generation of third party CTLs has helped ameliorate the problems related to donor availability and product generation time. In this review we aim to describe both the history of CTL use and current advances in the field.
AB - Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity. Adoptive cell therapy with cytotoxic T lymphocytes (CTL) has proven to be both efficacious and safe in the management of post-transplant viral infections. Recent advances have led to faster production of CTLs and broadened applications for their use. In particular, the generation of third party CTLs has helped ameliorate the problems related to donor availability and product generation time. In this review we aim to describe both the history of CTL use and current advances in the field.
KW - Adoptive immunotherapy
KW - Cytotoxic T lymphocytes
KW - Immunocompromised host
KW - Off-the-shelf
KW - Stem cell transplant
UR - http://www.scopus.com/inward/record.url?scp=85183545056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85183545056&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2024.01.003
DO - 10.1016/j.clml.2024.01.003
M3 - Review article
C2 - 38267354
AN - SCOPUS:85183545056
SN - 2152-2650
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
ER -